Compare SRI & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | KRRO |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 150.0M |
| IPO Year | 1997 | 2019 |
| Metric | SRI | KRRO |
|---|---|---|
| Price | $7.50 | $11.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $16.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 178.5K | 93.4K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $824,444,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.46 | ★ 181.46 |
| 52 Week Low | $4.60 | $5.20 |
| 52 Week High | $9.71 | $55.89 |
| Indicator | SRI | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 48.75 |
| Support Level | $7.08 | $10.35 |
| Resistance Level | $7.59 | $14.52 |
| Average True Range (ATR) | 0.44 | 0.94 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 74.66 | 54.08 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.